TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-14.07%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.34B
AUM Growth
+$2.34B
(-15%)
Cap. Flow
+$15.8M
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$14.9M |
| 2 |
Medtronic
MDT
|
$12.9M |
| 3 |
UnitedHealth
UNH
|
$7.69M |
| 4 |
Pfizer
PFE
|
$7.1M |
| 5 |
Merck
MRK
|
$7.1M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
$17M |
| 2 |
AstraZeneca
AZN
|
$11M |
| 3 |
Idexx Laboratories
IDXX
|
$9.46M |
| 4 |
Omega Healthcare
OHI
|
$7.02M |
| 5 |
Viatris
VTRS
|
$6.94M |
Sector Composition
| 1 | Healthcare | 94.39% |
| 2 | Real Estate | 2.48% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Johnson & Johnson
JNJ
$427B
| $133M | 5.7% | 1,032,628 +35,660 | +4% | +$4.6M |
|
2
Amgen
AMGN
$155B
| $132M | 5.65% | 677,855 | – | – |
|
3
Biogen
BIIB
$19.4B
| $119M | 5.09% | 394,902 +3,500 | +0.9% | +$1.05M |
|
4
Gilead Sciences
GILD
$140B
| $118M | 5.06% | 1,889,846 -52,471 | -3% | -$3.28M |
|
|
5
UnitedHealth
UNH
$281B
| $93.5M | 4% | 375,374 +30,888 | +9% | +$7.69M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $88.6M | 3.79% | 1,382,006 +69,656 | +5% | +$4.46M |
|
7
Illumina
ILMN
$15.8B
| $78.7M | 3.37% | 262,379 +19,662 | +8% | +$5.9M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $70.6M | 3.02% | 426,248 +18,013 | +4% | +$2.98M |
|
|
9
Pfizer
PFE
$141B
| $66.2M | 2.83% | 1,516,793 +162,700 | +12% | +$7.1M |
|
|
10
Merck
MRK
$210B
| $56.4M | 2.41% | 738,108 +92,900 | +14% | +$7.1M |
|
11
Regeneron Pharmaceuticals
REGN
$61.5B
| $51M | 2.18% | 136,422 -9,815 | -7% | -$3.67M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $48.3M | 2.07% | 496,288 +57,872 | +13% | +$5.63M |
|
13
AbbVie
ABBV
$372B
| $45.4M | 1.94% | 492,078 | – | – |
|
|
14
Medtronic
MDT
$119B
| $43.8M | 1.87% | 481,365 +141,926 | +42% | +$12.9M |
|
15
Thermo Fisher Scientific
TMO
$186B
| $42.9M | 1.84% | 191,895 +11,500 | +6% | +$2.57M |
|
16
Incyte
INCY
$16.5B
| $41M | 1.76% | 645,442 | – | – |
|
|
17
Viatris
VTRS
$12.3B
| $38.5M | 1.65% | 1,403,728 -253,289 | -15% | -$6.94M |
|
18
Elevance Health
ELV
$71.8B
| $37.1M | 1.59% | 141,147 | – | – |
|
|
19
Bristol-Myers Squibb
BMY
$96B
| $33.9M | 1.45% | 652,966 +286,902 | +78% | +$14.9M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $31.4M | 1.34% | 234,720 -14,116 | -6% | -$1.89M |
|
21
CVS Health
CVS
$92.8B
| $30.2M | 1.29% | 460,698 +59,597 | +15% | +$3.9M |
|
22
Abbott
ABT
$231B
| $28.3M | 1.21% | 391,719 | – | – |
|
23
Stryker
SYK
$150B
| $25.1M | 1.08% | 160,432 | – | – |
|
24
Eli Lilly
LLY
$657B
| $25M | 1.07% | 216,442 | – | – |
|
25
Novartis
NVS
$245B
| $25M | 1.07% | 291,717 -30,973 | -10% | -$2.66M |
|